ArticleScientific reports2026
Multiparametric MRI radiomics for noninvasive risk stratification of pediatric neuroblastoma: a pilot study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is the most common extracranial solid tumor in children, with risk stratification guiding therapy and prognosis. Although current risk stratification incorporates imaging-based staging, definitive risk assignment still relies on tissue and molecular characterization, highlighting the need for complementary noninvasive imaging biomarkers. The objectives were to evaluate the classification performance of multiparametric magnetic resonance imaging (MRI) radiomics for risk stratification of pediatric neuroblastoma and to determine how MRI sequences, feature-selection methods, and machine learning classifiers influence classification performance. This retrospective single-center feasibility study included 30 children with histologically confirmed neuroblastoma who underwent pre-treatment T1-, T2-, and diffusion-weighted MRI. From each sequence, 208 radiomic features were extracted from the whole-tumor volume and reduced using six feature-selection methods. Principal components of selected features trained six machine learning classifiers. Performance was assessed using a nested leave-one-out cross-validation framework, with predictions aggregated to one per patient before computing performance metrics, for binary classification of low/intermediate-risk versus high-risk neuroblastoma, using clinical risk classification as the reference standard, with pairwise differences evaluated by DeLong test and Benjamini-Hochberg correction. Among 30 children (mean age ± SD: 38 ± 40 months), the highest discrimination between risk groups was achieved using T2-weighted features and the combined T1w + T2w + ADC features, both with XGB (AUC = 0.88 ± 0.06 and 0.88 ± 0.07, respectively); however, the limited sample size prohibited the detection of significant differences between classifiers after correction for multiple comparisons. Features derived from T2-weighted and diffusion-weighted MRI contributed most to accurate classification. The chi-square feature selection method most frequently contributed to high-performing model configurations (30.8%). Multiparametric MRI radiomics based on whole-tumor volumes showed preliminary evidence of feasibility for noninvasive risk stratification of pediatric neuroblastoma, supporting its potential as a complementary imaging biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.